TROP2 as patient-tailoring but not prognostic biomarker

Via Peters

Introduction With more than 2.3 million estimated new cases in 2020, breast cancer (BC) is the most commonly diagnosed cancer (~24.5%) and the leading cause of cancer death (~15.5%) in women.1 Clinically, BC can be divided into different subtypes by their histopathological appearance and expression status of the estrogen receptor […]